European Archives - Page 351 of 1541 - European Medical Journal

CANYON: The Largest Interventional Trial in Becker

Sevasemten is an investigational agent that is currently not approved for use by any regulatory authority in any territory…

Obesity Severity and Tirzepatide’s Impact on Heart Failure Outcomes: New Insights

Tirzepatide improves outcomes in heart failure with obesity, with greatest physical benefits seen in those with higher BMI.

Pelvic Floor and Relaxation Exercises Ease Menstrual Pain

A growing body of research supports non-pharmacological treatments, particularly exercise, as effective in alleviating primary dysmenorrhea symptoms.

A New Era in Asthma and COPD: Interview with Sir Peter Barnes

For more than 40 years, I have been involved in asthma and COPD research. The clinical management of these diseases has changed…

Recent Developments in CLL Research

Talha Munir reviews the recent developments in chronic lymphocytic leukaemia research presented at the 2024 American Society of Hematology…

EMJ Hematology 13 [Supplement 3] 2025

In this insightful new interview, key opinion leader Talha Munir reviews the current landscape of chronic lymphocytic leukaemia (CLL), and…

Sotatercept Shows Sustained Benefit in Pulmonary Hypertension Study

A long-term study finds sotatercept continues to improve outcomes in patients with pulmonary arterial hypertension, with manageable safety risks.

Diabetes May Increase Bone Density Without Decreasing Fracture Risk

Understand how diabetes may raise bone density over time, but fracture risk remains.

Comparative Study Questions Cardiovascular Safety of Glipizide

Discover how new research found that glipizide carries higher cardiovascular risk than DPP4 inhibitors in Type 2 diabetes treatment.

Modifiable Risk Factors Behind Majority of Liver Cancers

At least 60% of liver cancer diagnoses are linked to modifiable risk factors and could be prevented through global interventions